ANIK · XBRL financial data

Anika Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ANIK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	130,457	147,794	156,236	166,662	119,907	112,819
Cost of goods and services sold	61,431	64,851	62,660	63,574	43,909	49,012
Gross profit	69,026	82,943	93,576	103,088	75,998	63,807
Research and development	23,431	27,327	28,182	32,690	25,544	25,770
Selling, general and administrative	60,063	74,096	84,794	95,847	55,555	49,088
Operating income (loss)	(28,322)	2,615	(19,400)	(87,639)	(5,101)	(11,051)
Income tax expense (benefit)	(4,642)	(1,707)	(3,887)	(2,660)	6,064	672
Net income (loss)	(23,982)	4,134	(14,859)	(82,667)	(56,385)	(10,880)
Earnings per share, basic USD per share	(1.69)	0.29	(1.02)	(5.64)	(3.83)	(0.76)
Earnings per share, diluted USD per share	(1.69)	0.28	(1.02)	(5.64)	(3.83)	(0.76)
Weighted average shares, basic thousands of shares	14,222	14,401	14,561	14,656	14,721	14,339
Weighted average shares, diluted thousands of shares	14,222	14,634	14,561	14,656	14,721	14,339

Fiscal years (ANIK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	95,817	94,386	86,327	72,867	55,629	57,481
Marketable securities	2,501	0	34,627	35,961	23,594	23,690
Marketable securities, non-current	0	0	0	0	0	0
Accounts receivable	24,102	29,843	34,627	35,961	23,594	23,690
Inventory	46,209	36,010	39,765	46,386	23,809	18,787
Prepaid and other current assets	8,754	8,289	8,828	8,095	5,494	3,400
Total current assets	177,383	168,528	169,547	163,309	113,652	103,358
Property and equipment, net	50,613	47,602	48,279	46,198	38,994	40,324
Right-of-use asset	22,619	20,957	30,696	28,767	25,685	25,939
Goodwill	8,413	7,781	7,339	7,571	7,125	8,054
Total assets	365,605	347,535	349,128	270,632	202,740	190,270
Accounts payable	8,984	7,633	9,074	9,860	5,617	6,041
Total current liabilities	36,867	29,795	27,914	31,059	23,306	21,908
Lease liability, non-current	20,879	19,240	28,817	26,904	24,014	24,196
Retained earnings	221,444	225,578	210,719	128,052	71,667	60,787
Total stockholders' equity	272,400	287,085	285,563	212,265	153,989	143,465
Total liabilities and equity	365,605	347,535	349,128	270,632	202,740	190,270
Common shares outstanding (cover page) thousands of shares	14,330	14,467	14,633	14,850	14,176	13,401

Fiscal years (ANIK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(23,982)	4,134	(14,859)	(82,667)	(56,385)	(10,880)
Stock-based compensation	5,386	11,085	14,315	15,243	13,130	10,084
Net cash from operating activities	13,065	8,397	4,409	(1,788)	5,403	11,188
Purchases of property and equipment	1,628	5,143	7,486	5,427	7,734	6,826
Net cash from investing activities	(71,264)	(3,118)	(7,486)	(5,427)	(8,334)	(401)
Share repurchases	0	0	0	5,000	10,914	9,485
Proceeds from long-term debt	50,000	0	0	—	—	—
Repayments of long-term debt	50,350	0	0	—	—	—
Net cash from financing activities	(3,774)	(6,779)	(4,852)	(6,324)	(12,729)	(10,551)
Net change in cash	(61,646)	(1,431)	(8,059)	(13,460)	(15,708)	322

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sight Sciences	77,402	24,923	(2,402)*	55.6M	15.2 quarters	Q3 FY26 10-QSep 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.